Bristol Myers Squibb announces Opdivo FDA approval for urothelial carcinoma
In a significant stride toward enhancing bladder cancer treatment, Bristol Myers Squibb (NYSE: BMY) announced the U.S. Food and Drug Administration (FDA) approval of Opdivo (nivolumab), in conjunction with cisplatin and gemcitabine, for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), the most prevalent form of bladder cancer. This approval […]